{"filing":{"accession_number":"0001171843-26-005793","cik":"0001898416","ticker":"ALVOW","company_name":"Alvotech","form":"6-K","filing_date":"2026-08-31","report_date":"2026-08-31","primary_document":"f6k_083126.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1898416/000117184326005793/f6k_083126.htm"},"events":[{"id":30499,"run_id":27950,"accession_number":"0001171843-26-005793","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Alvotech announced FDA acceptance for review of a Biologics License Application (BLA) for AVT80, a proposed interchangeable biosimilar to Entyvio for subcutaneous administration. This is a material regulatory milestone in the company's biosimilar development pipeline—FDA acceptance for review is a significant step toward potential market approval. While not a discrete M\u0026A event, covenant breach, or other specifically-named category, this regulatory advancement is clearly operational and strategic, affecting investor assessment of the company's pipeline progress and commercial prospects.","company_name":"Alvotech","ticker":"ALVOW","filing_date":"2026-08-31","form":"6-K","submitted_at":null,"items":[{"id":33109,"accession_number":"0001171843-26-005793","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Alvotech announced FDA acceptance for review of a Biologics License Application (BLA) for AVT80, a proposed interchangeable biosimilar to Entyvio for subcutaneous administration. This is a material regulatory milestone in the company's biosimilar development pipeline—FDA acceptance for review is a significant step toward potential market approval. While not a discrete M\u0026A event, covenant breach, or other specifically-named category, this regulatory advancement is clearly operational and strategic, affecting investor assessment of the company's pipeline progress and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-31T12:01:12.231695+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33109,"accession_number":"0001171843-26-005793","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Alvotech announced FDA acceptance for review of a Biologics License Application (BLA) for AVT80, a proposed interchangeable biosimilar to Entyvio for subcutaneous administration. This is a material regulatory milestone in the company's biosimilar development pipeline—FDA acceptance for review is a significant step toward potential market approval. While not a discrete M\u0026A event, covenant breach, or other specifically-named category, this regulatory advancement is clearly operational and strategic, affecting investor assessment of the company's pipeline progress and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-31T12:01:12.231695+00:00","company_name":"Alvotech","ticker":"ALVOW","filing_date":"2026-08-31"}]}